Immunotherapy Biotech Syndax Sets Terms On $66M IPO
Syndax Pharmaceuticals Inc., which is developing treatments designed to empower the body's immune response to tumors, set terms for a planned $66 million initial public offering on Monday, as life sciences...To view the full article, register now.
Already a subscriber? Click here to view full article